Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation??

By Caserta Donatella   Lisi Franco   Marci Roberto   Ciardo Francesca   Fazi Alessandra   Lisi Roberta   Moscarini Massimo  

Gynecological Endocrinology, Vol. 27, Iss. 11, 2011-11 ,pp. : 862-866

Informa Healthcare

Access to resources Recommend Favorite

Case report. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

By Itskovitz-Eldor J  

Human Reproduction, Vol. 13, Iss. 2, 1998-02 ,pp. : 294-295

Oxford University Press

Access to resources Recommend Favorite

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Recombinant follicle stimulating hormone

By  

Human Reproduction, Vol. 14, Iss. 6, 1999-06 ,pp. : 1418-1420

Oxford University Press

Access to resources Recommend Favorite

Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol

By Orvieto Raoul   Volodarsky Michael   Hod Eduard   Homburg Roy   Rabinson Jacob   Zohav Efraim   Anteby Eyal   Meltcer Simion  

Gynecological Endocrinology, Vol. 23, Iss. 8, 2007-08 ,pp. : 494-496

Informa Healthcare

Access to resources Recommend Favorite